Moxonidine Effects on Neuropeptide Y
Primary Purpose
Obesity, Hypertension
Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Moxonidine
Sponsored by

About this trial
This is an interventional treatment trial for Obesity focused on measuring hypertension, obesity, Neuropeptide Y, moxonidine
Eligibility Criteria
Inclusion Criteria:
- treatment-naïve subjects with mild or moderate hypertension according to Joint National Committee 7 and European Society Hypertension / European Society Cardiology 2008 (Stage 1: Systolic Blood Pressure =140-159 mmHg, Diastolic Blood Pressure =90-99 mmHg, and Stage 2: Systolic=160-179 mmHg, Diastolic=100-109 mmHg) that require monotherapy
Exclusion Criteria:
- age beyond 25-75 years,
- not taking currently anti-hypertensive medication
- not taking anti-diabetic or lipid lowering medication and other diseases or conditions that may influence blood pressure, heart rate and catecholamines' and Neuropeptide Y levels, including anemia, fever, stage III hypertension, coronary artery disease, recent (less than 6 months) myocardial infraction or stroke, heart failure, secondary hypertension, diabetes mellitus, abnormal thyroid status or other obesity-related endocrinopathies, pregnancy, kidney failure, alcohol abuse, malignancies, depression or other psychiatric illnesses, such as schizophrenia,
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Group
Arm Description
0.6 mg moxonidine daily
Outcomes
Primary Outcome Measures
serum Neuropeptide Y levels
ELISA
systolic blood pressure
mmHg
diastolic blood pressure
mmHg
Secondary Outcome Measures
Weight
kg
Body Mass Index
kg/m2
Total Cholesterol
mg/dl
HDL Cholesterol
mg/dl
LDL Cholesterol
mg/dl
Serum triglycerides
mg/dl
Full Information
NCT ID
NCT05147753
First Posted
November 18, 2021
Last Updated
November 24, 2021
Sponsor
Aristotle University Of Thessaloniki
1. Study Identification
Unique Protocol Identification Number
NCT05147753
Brief Title
Moxonidine Effects on Neuropeptide Y
Official Title
Effects of Moxonidine Administration on Serum Neuropeptide Y Levels in Hypertensive Individuals: A Prospective Observational Study
Study Type
Interventional
2. Study Status
Record Verification Date
November 2021
Overall Recruitment Status
Completed
Study Start Date
January 11, 2010 (Actual)
Primary Completion Date
June 30, 2014 (Actual)
Study Completion Date
June 30, 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Aristotle University Of Thessaloniki
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Treatment with monotherapy of moxonidine 0.6 mg daily in treatment-naïve subjects with mild or moderate hypertension
Detailed Description
Treatment with 0.6 mg moxonidine daily in treatment-naïve subjects with mild or moderate hypertension according to guidelines (Stage 1: Systolic Blood Pressure =140-159 mmHg, Diastolic Blood Pressure =90-99 mmHg, and Stage 2: systolic blood pressure=160-179 mmHg, diastolic blood pressure=100-109 mmHg) that require monotherapy and reevaluation after 12 weeks
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity, Hypertension
Keywords
hypertension, obesity, Neuropeptide Y, moxonidine
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
90 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Group
Arm Type
Experimental
Arm Description
0.6 mg moxonidine daily
Intervention Type
Drug
Intervention Name(s)
Moxonidine
Intervention Description
0.6 mg moxonidine daily
Primary Outcome Measure Information:
Title
serum Neuropeptide Y levels
Description
ELISA
Time Frame
12 weeks
Title
systolic blood pressure
Description
mmHg
Time Frame
12 weeks
Title
diastolic blood pressure
Description
mmHg
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
Weight
Description
kg
Time Frame
12 weeks
Title
Body Mass Index
Description
kg/m2
Time Frame
12 weeks
Title
Total Cholesterol
Description
mg/dl
Time Frame
12 weeks
Title
HDL Cholesterol
Description
mg/dl
Time Frame
12 weeks
Title
LDL Cholesterol
Description
mg/dl
Time Frame
12 weeks
Title
Serum triglycerides
Description
mg/dl
Time Frame
12 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
25 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
treatment-naïve subjects with mild or moderate hypertension according to Joint National Committee 7 and European Society Hypertension / European Society Cardiology 2008 (Stage 1: Systolic Blood Pressure =140-159 mmHg, Diastolic Blood Pressure =90-99 mmHg, and Stage 2: Systolic=160-179 mmHg, Diastolic=100-109 mmHg) that require monotherapy
Exclusion Criteria:
age beyond 25-75 years,
not taking currently anti-hypertensive medication
not taking anti-diabetic or lipid lowering medication and other diseases or conditions that may influence blood pressure, heart rate and catecholamines' and Neuropeptide Y levels, including anemia, fever, stage III hypertension, coronary artery disease, recent (less than 6 months) myocardial infraction or stroke, heart failure, secondary hypertension, diabetes mellitus, abnormal thyroid status or other obesity-related endocrinopathies, pregnancy, kidney failure, alcohol abuse, malignancies, depression or other psychiatric illnesses, such as schizophrenia,
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Eleni Karlafti, MD, PhD
Organizational Affiliation
AHEPA University Hospital
Official's Role
Principal Investigator
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Moxonidine Effects on Neuropeptide Y
We'll reach out to this number within 24 hrs